

# Punnee Pitisuttithum

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8719926/publications.pdf>

Version: 2024-02-01

114  
papers

13,431  
citations

76326

40  
h-index

25787

108  
g-index

116  
all docs

116  
docs citations

116  
times ranked

10123  
citing authors

#	ARTICLE	IF	CITATIONS
1	Social restriction versus herd immunity policies in the early phase of the SARS-CoV-2 pandemic: A mathematical modelling study. <i>Asian Pacific Journal of Allergy and Immunology</i> , 2022, , .	0.4	4
2	COVID-19 vaccine strategies must focus on severe disease and global equity. <i>Lancet</i> , The, 2022, 399, 406-410.	13.7	55
3	A Quantitative Approach to Unravel the Role of Host Genetics in IgG-Fc $\gamma$ R Complex Formation After Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 820148.	4.8	1
4	Safety and immunogenicity of an inactivated recombinant Newcastle disease virus vaccine expressing SARS-CoV-2 spike: Interim results of a randomised, placebo-controlled, phase 1 trial. <i>EClinicalMedicine</i> , 2022, 45, 101323.	7.1	26
5	Long-term effectiveness of human papillomavirus vaccines among adult women: A real-world scenario. <i>Vaccine</i> , 2022, 40, 1968-1976.	3.8	4
6	Adherence and Health Problems in Thai Travellers Living with HIV. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 128.	2.3	0
7	Viewpoint of a WHO Advisory Group Tasked to Consider Establishing a Closely-monitored Challenge Model of Coronavirus Disease 2019 (COVID-19) in Healthy Volunteers. <i>Clinical Infectious Diseases</i> , 2021, 72, 2035-2041.	5.8	15
8	Etiology, Clinical Course, and Outcomes of Pneumonia in the Elderly: A Retrospective and Prospective Cohort Study in Thailand. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 104, 2009-2016.	1.4	17
9	Vaccine development lessons between HIV and COVID-19. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 759-761.	9.1	3
10	Antibody persistence 2 and 3 years after booster vaccination of adolescents with recombinant acellular pertussis monovalent aPgen or combined TdapGen vaccines. <i>EClinicalMedicine</i> , 2021, 37, 100976.	7.1	9
11	Risk Factors for HIV sero-conversion in a high incidence cohort of men who have sex with men and transgender women in Bangkok, Thailand. <i>EClinicalMedicine</i> , 2021, 38, 101033.	7.1	4
12	Monocyte-derived transcriptome signature indicates antibody-dependent cellular phagocytosis as a potential mechanism of vaccine-induced protection against HIV-1. <i>ELife</i> , 2021, 10, .	6.0	12
13	A Research and Development (R&D) roadmap for influenza vaccines: Looking toward the future. <i>Vaccine</i> , 2021, 39, 6573-6584.	3.8	32
14	A systems approach to elucidate personalized mechanistic complexities of antibody-Fc receptor activation post-vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100386.	6.5	8
15	Three-Year Follow-up of 2-Dose Versus 3-Dose HPV Vaccine. <i>Pediatrics</i> , 2021, 147, .	2.1	11
16	Knowledge, attitude, and practices toward COVID-19 among the international travelers in Thailand. <i>Tropical Diseases, Travel Medicine and Vaccines</i> , 2021, 7, 29.	2.2	4
17	Human Papillomavirus Vaccine Efficacy and Effectiveness against Cancer. <i>Vaccines</i> , 2021, 9, 1413.	4.4	77
18	A live attenuated H5N2 prime-inactivated H5N1 boost vaccination induces influenza virus hemagglutinin stalk specific antibody responses. <i>Vaccine</i> , 2020, 38, 852-858.	3.8	1

#	ARTICLE	IF	CITATIONS
19	Long-term immunogenicity, effectiveness, and safety of nine-valent human papillomavirus vaccine in girls and boys 9 to 15 years of age: Interim analysis after 8 years of follow-up. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2020, 10, 100203.	4.5	34
20	Selecting participants fairly for controlled human infection studies. <i>Bioethics</i> , 2020, 34, 771-784.	1.4	1
21	Late boosting of the RV144 regimen with AIDSVAX B/E and ALVAC-HIV in HIV-uninfected Thai volunteers: a double-blind, randomised controlled trial. <i>Lancet HIV</i> , 2020, 7, e238-e248.	4.7	33
22	Prophylactic HIV vaccine: vaccine regimens in clinical trials and potential challenges. <i>Expert Review of Vaccines</i> , 2020, 19, 133-142.	4.4	19
23	Boosting with AIDSVAX B/E Enhances Env Constant Region 1 and 2 Antibody-Dependent Cellular Cytotoxicity Breadth and Potency. <i>Journal of Virology</i> , 2020, 94, .	3.4	19
24	HIV vaccine delayed boosting increases Env variable region 2-specific antibody effector functions. <i>JCI Insight</i> , 2020, 5, .	5.0	18
25	Protein-based, but not viral vector alone, HIV vaccine boosting drives an IgG1-biased polyfunctional humoral immune response. <i>JCI Insight</i> , 2020, 5, .	5.0	12
26	Landscapes of binding antibody and T-cell responses to pox-protein HIV vaccines in Thais and South Africans. <i>PLoS ONE</i> , 2020, 15, e0226803.	2.5	16
27	A review of epidemic preparedness for influenza through local vaccine production: national security for Thailand. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2440-2445.	3.3	1
28	HIV Incidence and Risk Behaviours of People Who Inject Drugs in Bangkok, 1995-2012. <i>EClinicalMedicine</i> , 2019, 9, 44-51.	7.1	13
29	HIV-1 Envelope Glycoproteins from Diverse Clades Differentiate Antibody Responses and Durability among Vaccinees. <i>Journal of Virology</i> , 2018, 92, .	3.4	46
30	HIV-1-Specific IgA Monoclonal Antibodies from an HIV-1 Vaccinee Mediate Galactosylceramide Blocking and Phagocytosis. <i>Journal of Virology</i> , 2018, 92, .	3.4	45
31	Impact of Dengue Vaccination on Serological Diagnosis: Insights From Phase III Dengue Vaccine Efficacy Trials. <i>Clinical Infectious Diseases</i> , 2018, 66, 1164-1172.	5.8	16
32	A genetically inactivated two-component acellular pertussis vaccine, alone or combined with tetanus and reduced-dose diphtheria vaccines, in adolescents: a phase 2/3, randomised controlled non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2018, 18, 58-67.	9.1	22
33	Periods of high dengue transmission defined by rainfall do not impact efficacy of dengue vaccine in regions of endemic disease. <i>PLoS ONE</i> , 2018, 13, e0207878.	2.5	5
34	Vaccine Update: Recent Progress With Novel Vaccines, and New Approaches to Safety Monitoring and Vaccine Shortage. <i>Journal of Clinical Pharmacology</i> , 2018, 58, S123-S139.	2.0	6
35	Antibody persistence after vaccination of adolescents with monovalent and combined acellular pertussis vaccines containing genetically inactivated pertussis toxin: a phase 2/3 randomised, controlled, non-inferiority trial. <i>Lancet Infectious Diseases</i> , 2018, 18, 1260-1268.	9.1	28
36	Characterization of HIV-1 gp120 antibody specificities induced in anogenital secretions of RV144 vaccine recipients after late boost immunizations. <i>PLoS ONE</i> , 2018, 13, e0196397.	2.5	14

#	ARTICLE	IF	CITATIONS
37	Modulation of Vaccine-Induced CD4 T Cell Functional Profiles by Changes in Components of HIV Vaccine Regimens in Humans. <i>Journal of Virology</i> , 2018, 92, .	3.4	7
38	Evaluation of a mosaic HIV-1 vaccine in a multicentre, randomised, double-blind, placebo-controlled, phase 1/2a clinical trial (APPROACH) and in rhesus monkeys (NHP 13-19). <i>Lancet</i> , The, 2018, 392, 232-243.	13.7	269
39	Novel Strategy To Adapt Simian-Human Immunodeficiency Virus E1 Carrying <i>env</i> from an RV144 Volunteer to Rhesus Macaques: Coreceptor Switch and Final Recovery of a Pathogenic Virus with Exclusive R5 Tropism. <i>Journal of Virology</i> , 2018, 92, .	3.4	3
40	A novel mechanism linking memory stem cells with innate immunity in protection against HIV-1 infection. <i>Scientific Reports</i> , 2017, 7, 1057.	3.3	10
41	Randomized, Double-Blind Evaluation of Late Boost Strategies for HIV-Uninfected Vaccine Recipients in the RV144 HIV Vaccine Efficacy Trial. <i>Journal of Infectious Diseases</i> , 2017, 215, 1255-1263.	4.0	57
42	Safety and immunogenicity of a live attenuated influenza H5 candidate vaccine strain A/17/turkey/Turkey/05/133 H5N2 and its priming effects for potential pre-pandemic use: a randomised, double-blind, placebo-controlled trial. <i>Lancet Infectious Diseases</i> , The, 2017, 17, 833-842.	9.1	27
43	Impact of baseline covariates on the immunogenicity of the 9-valent HPV vaccine – A combined analysis of five phase III clinical trials. <i>Papillomavirus Research (Amsterdam, Netherlands)</i> , 2017, 3, 105-115.	4.5	22
44	Comparison of Antibody Responses Induced by RV144, VAX003, and VAX004 Vaccination Regimens. <i>AIDS Research and Human Retroviruses</i> , 2017, 33, 410-423.	1.1	38
45	Monoclonal Antibodies, Derived from Humans Vaccinated with the RV144 HIV Vaccine Containing the HVEM Binding Domain of Herpes Simplex Virus (HSV) Glycoprotein D, Neutralize HSV Infection, Mediate Antibody-Dependent Cellular Cytotoxicity, and Protect Mice from Ocular Challenge with HSV-1. <i>Journal of Virology</i> , 2017, 91, .	3.4	19
46	Immune responses to intradermal and intramuscular inactivated influenza vaccine among older age group. <i>Vaccine</i> , 2017, 35, 7339-7346.	3.8	21
47	Antibody to HSV gD peptide induced by vaccination does not protect against HSV-2 infection in HSV-2 seronegative women. <i>PLoS ONE</i> , 2017, 12, e0176428.	2.5	12
48	V1V2-specific complement activating serum IgG as a correlate of reduced HIV-1 infection risk in RV144. <i>PLoS ONE</i> , 2017, 12, e0180720.	2.5	55
49	Boosting of HIV envelope CD4 binding site antibodies with long variable heavy third complementarity determining region in the randomized double blind RV305 HIV-1 vaccine trial. <i>PLoS Pathogens</i> , 2017, 13, e1006182.	4.7	38
50	Resource Use and Costs of Dengue: Analysis of Data from Phase III Efficacy Studies of a Tetravalent Dengue Vaccine. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 1898-1903.	1.4	5
51	F-108 – The role of a dual pre- and post- entry innate and adaptive immune mechanism in protection against HIV-1 infection. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 63.	2.1	0
52	Neutralization Takes Precedence Over IgG or IgA Isotype-related Functions in Mucosal HIV-1 Antibody-mediated Protection. <i>EBioMedicine</i> , 2016, 14, 97-111.	6.1	47
53	Clinical Trial of an Oral Live <i>Shigella sonnei</i> Vaccine Candidate, WRSS1, in Thai Adults. <i>Vaccine Journal</i> , 2016, 23, 564-575.	3.1	25
54	The first licensed dengue vaccine: an important tool for integrated preventive strategies against dengue virus infection. <i>Expert Review of Vaccines</i> , 2016, 15, 795-798.	4.4	30

#	ARTICLE	IF	CITATIONS
55	Tissue memory B cell repertoire analysis after ALVAC/AIDS VAX B/E gp120 immunization of rhesus macaques. <i>JCI Insight</i> , 2016, 1, e88522.	5.0	10
56	Health education and factors influencing acceptance of and willingness to pay for influenza vaccination among older adults. <i>BMC Geriatrics</i> , 2015, 15, 136.	2.7	36
57	A 9-Valent HPV Vaccine Against Infection and Intraepithelial Neoplasia in Women. <i>Obstetrical and Gynecological Survey</i> , 2015, 70, 446-448.	0.4	4
58	Accuracy of Clinical Diagnosis of Dengue Episodes in the RV144 HIV Vaccine Efficacy Trial in Thailand. <i>PLoS ONE</i> , 2015, 10, e0127998.	2.5	2
59	Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. <i>PLoS Pathogens</i> , 2015, 11, e1005042.	4.7	145
60	COMPASS identifies T-cell subsets correlated with clinical outcomes. <i>Nature Biotechnology</i> , 2015, 33, 610-616.	17.5	232
61	A 9-Valent HPV Vaccine against Infection and Intraepithelial Neoplasia in Women. <i>New England Journal of Medicine</i> , 2015, 372, 711-723.	27.0	1,090
62	Immunogenicity and Safety of a 9-Valent HPV Vaccine. <i>Pediatrics</i> , 2015, 136, e28-e39.	2.1	105
63	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>PLoS Computational Biology</i> , 2015, 11, e1003973.	3.2	51
64	Infant HIV Type 1 gp120 Vaccination Elicits Robust and Durable Anti-V1V2 Immunoglobulin G Responses and Only Rare Envelope-Specific Immunoglobulin A Responses. <i>Journal of Infectious Diseases</i> , 2015, 211, 508-517.	4.0	57
65	HLA class II genes modulate vaccine-induced antibody responses to affect HIV-1 acquisition. <i>Science Translational Medicine</i> , 2015, 7, 296ra112.	12.4	47
66	Machine Learning Methods Enable Predictive Modeling of Antibody Feature:Function Relationships in RV144 Vaccinees. <i>PLoS Computational Biology</i> , 2015, 11, e1004185.	3.2	50
67	9-Valent HPV vaccine for cancers, pre-cancers and genital warts related to HPV. <i>Expert Review of Vaccines</i> , 2015, 14, 1405-1419.	4.4	38
68	IgG Antibody Responses to Recombinant gp120 Proteins, gp70V1/V2 Scaffolds, and a CyclicV2 Peptide in Thai Phase I/II Vaccine Trials Using Different Vaccine Regimens. <i>AIDS Research and Human Retroviruses</i> , 2015, 31, 1178-1186.	1.1	14
69	Structural analysis of the unmutated ancestor of the HIV-1 envelope V2 region antibody CH58 isolated from an RV144 vaccine efficacy trial vaccinee. <i>EBioMedicine</i> , 2015, 2, 713-722.	6.1	13
70	Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to $\alpha 4\beta 7$ Integrin Receptor. <i>PLoS ONE</i> , 2015, 10, e0143895.	2.5	41
71	Aggregate complexes of HIV-1 induced by multimeric antibodies. <i>Retrovirology</i> , 2014, 11, 78.	2.0	26
72	HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities. <i>Journal of Virology</i> , 2014, 88, 7715-7726.	3.4	169

#	ARTICLE	IF	CITATIONS
73	Antibody Light-Chain-Restricted Recognition of the Site of Immune Pressure in the RV144 HIV-1 Vaccine Trial Is Phylogenetically Conserved. <i>Immunity</i> , 2014, 41, 909-918.	14.3	65
74	Integrated Systems Biology Analysis Reveals Contrasting Role for Innate Immune Response Genes in Conferring Risk of Infection in RV144 Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A15-A16.	1.1	1
75	Vaccine-Induced Env V1-V2 IgG3 Correlates with Lower HIV-1 Infection Risk and Declines Soon After Vaccination. <i>Science Translational Medicine</i> , 2014, 6, 228ra39.	12.4	412
76	Polyfunctional Fc-Effector Profiles Mediated by IgG Subclass Selection Distinguish RV144 and VAX003 Vaccines. <i>Science Translational Medicine</i> , 2014, 6, 228ra38.	12.4	367
77	Expectation of Volunteers Towards the Vaccine Efficacy of the Prime-Boost HIV Vaccine Phase III Trial During Unblinding. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, 1041-1045.	1.1	3
78	Comprehensive Sieve Analysis of Breakthrough HIV-1 Sequences in the RV144 Vaccine Efficacy Trial. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A25-A26.	1.1	0
79	RV306, an Evaluation of a 48 Week ALVAC-HIV AIDS VAX B/E Vaccination Regimen in Thailand: Participation Rates for Optional Specimen Collections. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A264-A264.	1.1	4
80	HIV-specific antibody-dependent phagocytosis matures during HIV infection. <i>Immunology and Cell Biology</i> , 2014, 92, 679-687.	2.3	29
81	Clinical efficacy and safety of a novel tetravalent dengue vaccine in healthy children in Asia: a phase 3, randomised, observer-masked, placebo-controlled trial. <i>Lancet</i> , The, 2014, 384, 1358-1365.	13.7	829
82	Vaccine-Induced HIV-1 Envelope gp120 Constant Region 1-Specific Antibodies Expose a CD4-Inducible Epitope and Block the Interaction of HIV-1 gp140 with Galactosylceramide. <i>Journal of Virology</i> , 2014, 88, 9406-9417.	3.4	16
83	HLA class I, KIR, and genome-wide SNP diversity in the RV144 Thai phase 3 HIV vaccine clinical trial. <i>Immunogenetics</i> , 2014, 66, 299-310.	2.4	14
84	Attribution of 12 High-Risk Human Papillomavirus Genotypes to Infection and Cervical Disease. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1997-2008.	2.5	137
85	FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial. <i>Journal of Clinical Investigation</i> , 2014, 124, 3879-3890.	8.2	99
86	Vaccine-Induced IgG Antibodies to V1V2 Regions of Multiple HIV-1 Subtypes Correlate with Decreased Risk of HIV-1 Infection. <i>PLoS ONE</i> , 2014, 9, e87572.	2.5	248
87	Family Based Directly Observed Therapy on Culture Conversion in Newly Diagnosed Pulmonary Tuberculosis Patients. <i>American Journal of Public Health Research</i> , 2014, 2, 147-152.	0.3	0
88	Costs of Chronic Hepatitis B patients in a developing country. <i>Journal of Nursing Education and Practice</i> , 2014, 4, .	0.2	0
89	Safety and immune responses following administration of H1N1 live attenuated influenza vaccine in Thais. <i>Vaccine</i> , 2013, 31, 1503-1509.	3.8	12
90	Issues in Women's Participation in a Phase III Community HIV Vaccine Trial in Thailand. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1524-1534.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Vaccine Induction of Antibodies against a Structurally Heterogeneous Site of Immune Pressure within HIV-1 Envelope Protein Variable Regions 1 and 2. <i>Immunity</i> , 2013, 38, 176-186.	14.3	374
92	Beyond RV144 Efficacy Results: An Update. <i>Procedia in Vaccinology</i> , 2013, 7, 49-56.	0.4	8
93	Infectious Virion Capture by HIV-1 gp120-Specific IgG from RV144 Vaccinees. <i>Journal of Virology</i> , 2013, 87, 7828-7836.	3.4	59
94	Dengue and Other Common Causes of Acute Febrile Illness in Asia: An Active Surveillance Study in Children. <i>PLoS Neglected Tropical Diseases</i> , 2013, 7, e2331.	3.0	99
95	Antigenicity and Immunogenicity of RV144 Vaccine AIDSVAX Clade E Envelope Immunogen Is Enhanced by a gp120 N-Terminal Deletion. <i>Journal of Virology</i> , 2013, 87, 1554-1568.	3.4	97
96	Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9019-9024.	7.1	371
97	Plasma IgG to Linear Epitopes in the V2 and V3 Regions of HIV-1 gp120 Correlate with a Reduced Risk of Infection in the RV144 Vaccine Efficacy Trial. <i>PLoS ONE</i> , 2013, 8, e75665.	2.5	214
98	An HIV Vaccine for South-East Asia—Opportunities and Challenges. <i>Vaccines</i> , 2013, 1, 348-366.	4.4	5
99	Clinical Factors for Severity of Plasmodium falciparum Malaria in Hospitalized Adults in Thailand. <i>PLoS ONE</i> , 2013, 8, e71503.	2.5	15
100	Magnitude and Breadth of the Neutralizing Antibody Response in the RV144 and Vax003 HIV-1 Vaccine Efficacy Trials. <i>Journal of Infectious Diseases</i> , 2012, 206, 431-441.	4.0	273
101	Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. <i>Journal of Virology</i> , 2012, 86, 11521-11532.	3.4	357
102	The Thai Phase III HIV Type 1 Vaccine Trial (RV144) Regimen Induces Antibodies That Target Conserved Regions Within the V2 Loop of gp120. <i>AIDS Research and Human Retroviruses</i> , 2012, 28, 1444-1457.	1.1	191
103	Establishment of a Shigella sonnei human challenge model in Thailand. <i>Vaccine</i> , 2012, 30, 7040-7045.	3.8	25
104	Immune-Correlates Analysis of an HIV-1 Vaccine Efficacy Trial. <i>New England Journal of Medicine</i> , 2012, 366, 1275-1286.	27.0	1,699
105	Safety and Reactogenicity of Canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E Vaccination in an Efficacy Trial in Thailand. <i>PLoS ONE</i> , 2011, 6, e27837.	2.5	48
106	Accelerating the development of an AIDS vaccine: the AIDS vaccine for Asia Network (Avan). <i>Southeast Asian Journal of Tropical Medicine and Public Health</i> , 2011, 42, 1130-46.	1.0	4
107	Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in Thailand. <i>New England Journal of Medicine</i> , 2009, 361, 2209-2220.	27.0	2,748
108	HIV vaccine research in Thailand: lessons learned. <i>Expert Review of Vaccines</i> , 2008, 7, 311-317.	4.4	17

#	ARTICLE	IF	CITATIONS
109	Social harms in injecting drug users participating in the first phase III HIV vaccine trial in Thailand. <i>Journal of the Medical Association of Thailand = Chotmaihet Thangphaet</i> , 2007, 90, 2442-8.	0.1	6
110	Randomized, Double-blind, Placebo-controlled Efficacy Trial of a Bivalent Recombinant Glycoprotein 120 HIV-1 Vaccine among Injection Drug Users in Bangkok, Thailand. <i>Journal of Infectious Diseases</i> , 2006, 194, 1661-1671.	4.0	755
111	HIV-1 Prophylactic Vaccine Trials in Thailand. <i>Current HIV Research</i> , 2005, 3, 17-30.	0.5	22
112	Activity of posaconazole in the treatment of central nervous system fungal infections. <i>Journal of Antimicrobial Chemotherapy</i> , 2005, 56, 745-755.	3.0	225
113	Phase I/II Study of a Candidate Vaccine Designed Against the B and E Subtypes of HIV-1. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 37, 1160-1165.	2.1	65
114	Safety and Immunogenicity of Combinations of Recombinant Subtype E and B Human Immunodeficiency Virus Type 1 Envelope Glycoprotein 120 Vaccines in Healthy Thai Adults. <i>Journal of Infectious Diseases</i> , 2003, 188, 219-227.	4.0	65